Adaptive Phage Therapeutics
- Company typePrivate
- Founded2016
- HeadquartersBethesda, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Adaptive Phage Therapeutics firmographics
Firmographics- Name
- Adaptive Phage Therapeutics
- Legal name
- Adaptive Phage Therapeutics
- Website
- https://aphage.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Adaptive Phage Therapeutics industry classification
Industry- Product category
- Phage-Based Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Phage & Phage-Derived Microbiome Modulators (HLAAAFAF)
Keywords
Where Adaptive Phage Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Bethesda
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Adaptive Phage Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Adaptive Phage Therapeutics product offering
Product offeringCore offering
Adaptive Phage Therapeutics is a clinical-stage biotechnology company developing precision bacteriophage therapies for treating multi-drug resistant bacterial infections. Its core offering, PhageBank™, is a proprietary library of bacteriophages that can be rapidly matched to specific bacterial pathogens to deliver targeted phage-based treatments. The company was advancing Phase 1/2 clinical trials for diabetic foot osteomyelitis before being acquired by BiomX Ltd. in March 2024.
Product overview
Adaptive Phage Therapeutics is a clinical-stage biotechnology company developing precision bacteriophage therapies for antibiotic-resistant bacterial infections. The company's primary offering is the PhageBank™ platform, which provides phage-based treatments designed to target and eliminate drug-resistant bacteria. The company was acquired by BiomX Ltd. in March 2024.
Differentiator
Problem solved
Functional benefit
Products and services
- PhageBank™ PhageBank™ is a proprietary precision bacteriophage therapy platform and library designed to target multi-drug resistant bacterial infections. It enables rapid matching of phage cocktails to specific bacterial pathogens for clinical use, with development focused on indications such as diabetic foot osteomyelitis.
Companies that use Adaptive Phage Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Adaptive Phage Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Adaptive Phage Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- BiomX Ltd.coreBiomX Ltd., an Israeli firm, acquired Adaptive Phage Therapeutics in March 2024. This acquisition represents a strategic consolidation in the phage therapy sector, with BiomX expanding its capabilities through the acquisition of this US-based clinical-stage biotechnology company specializing in precision bacteriophage therapies.
Scale indicators5 records
Recent moves4 records
Expansion highlights4 records
Adaptive Phage Therapeutics competitors and assessment
Company assessmentDirect peers
- BiomX Ltd. Acquirer and parent company of Adaptive Phage Therapeutics; Israeli clinical-stage biotech developing phage-based therapeutics targeting AMR-related bacterial infections, with overlapping pipeline in cystic fibrosis and other indications.
- Armata Pharmaceuticals: Clinical-stage phage therapy company developing engineered bacteriophage cocktails for antibiotic-resistant infections including Pseudomonas aeruginosa and Staphylococcus aureus; directly comparable therapeutic platform and AMR focus.
- ContraFect Corporation: Clinical-stage biotech developing direct lytic agents (lysins) and other novel antimicrobials for serious antibiotic-resistant infections, including MRSA bacteremia; competes in the same therapeutic area with adjacent biological modality.
- Locus Biosciences: Clinical-stage company developing engineered bacteriophage products, including CRISPR-enhanced phage therapies, for treatment of antibiotic-resistant bacterial infections; overlapping platform technology and clinical development stage.
- Pherecydes Pharma: French clinical-stage biotech developing phage therapy products targeting antibiotic-resistant bacterial infections, including Pseudomonas and Staph aureus; comparable clinical-stage phage therapy pipeline in Europe.
Emerging players
- Eligo Bioscience: Developer of phage-based precision medicines using engineered payloads (e.g., CRISPR) to selectively target pathogenic bacteria; earlier-stage but directly comparable platform approach for microbiome and AMR applications.
- SNIPR Biome: Clinical-stage company developing CRISPR-based phage products (SNIPR001) to target antimicrobial-resistant bacteria in the gut of immunocompromised patients; adjacent modality with overlapping AMR application.
- Centauri Therapeutics: UK-based biotech developing novel antimicrobial approaches including Antibody-Bactericidal Conjugates targeting serious drug-resistant infections; comparable AMR focus with adjacent biological modality.
Regional players
- TechnoPhage: Portuguese clinical-stage biotech developing bacteriophage-based products for bacterial infections; comparable therapeutic modality and AMR focus, primarily serving European markets.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks3 records
Key highlights5 records
Customer concentration
Adaptive Phage Therapeutics social profiles
Digital presenceAdaptive Phage Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Adaptive Phage Therapeutics leadership team
Management profileNumber of profiles
Profiles7 records
Adaptive Phage Therapeutics funding detail
Funding detailFunding overview
Funding rounds9 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Adaptive Phage Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Adaptive Phage Therapeutics
What does Adaptive Phage Therapeutics do?
Adaptive Phage Therapeutics is a clinical-stage biotechnology company developing precision bacteriophage therapies for treating multi-drug resistant bacterial infections. Its core offering, PhageBank™, is a proprietary library of bacteriophages that can be rapidly matched to specific bacterial pathogens to deliver targeted phage-based treatments. The company was advancing Phase 1/2 clinical trials for diabetic foot osteomyelitis before being acquired by BiomX Ltd. in March 2024.
Is Adaptive Phage Therapeutics a public or private company?
Adaptive Phage Therapeutics is a private company. It is classified as corporate owned and is currently acquired.
When was Adaptive Phage Therapeutics founded?
Adaptive Phage Therapeutics was founded in 2016. It employs 11 to 50 people.
Where is Adaptive Phage Therapeutics based?
Adaptive Phage Therapeutics is headquartered in Bethesda, United States, in the North America region.
Who are Adaptive Phage Therapeutics's main competitors?
Direct peers on record are BiomX Ltd., Armata Pharmaceuticals, ContraFect Corporation, Locus Biosciences and Pherecydes Pharma. Emerging players are Eligo Bioscience, SNIPR Biome and Centauri Therapeutics. TechnoPhage is listed as a regional player.
Does Adaptive Phage Therapeutics have an API?
No public API is recorded for Adaptive Phage Therapeutics.
What industry is Adaptive Phage Therapeutics in?
Adaptive Phage Therapeutics's product category is Phage-Based Therapeutics. Its primary akta.pro industry code is HLAAAFAF, Phage & Phage-Derived Microbiome Modulators. Its NAICS code is 541714 and its SIC code is 2836.